-2.46%
-14.96%
-25.01%
-48.56%
-55.43%
53.33%
190.39%
30.00030.00028.00028.00026.00026.00024.00024.00022.00022.00020.00020.00018.00018.00011/29/202411/29/202412/10/202412/10/202412/21/202412/21/20241/1/20251/1/20251/13/20251/13/20251/24/20251/24/20252/4/20252/4/20252/15/20252/15/2025
Download SVG
Download PNG
Download CSV

Company Description

IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics.The company's lead product candidates include IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase I clinical trial for patients with solid tumors having methylthioadenosine phosphorylase deletions; and IDE196, a protein kinase C inhibitor that is in Phase I/II clinical trial for genetically defined cancers having GNAQ or GNA11 gene mutations.Its preclinical pipeline includes various synthetic lethality programs targeting PARG inhibitor in tumors for patients having tumors with a defined biomarker based on genetic mutations and/or molecular signatures; Pol Theta inhibitors in tumors with BRCA or other homologous recombination deficiency mutations; and WRN inhibitors in tumors with high microsatellite instability.


The company has a research collaboration agreement with Cancer Research UK and the University of Manchester to develop small molecule inhibitors of Poly (ADP-ribose) glycohydrolase; and a clinical trial collaboration and supply agreement with Pfizer Inc.for Phase I/II study in metastatic uveal melanoma, skin melanoma, and other solid tumors, as well as a strategic partnership with GlaxoSmithKline plc.IDEAYA Biosciences, Inc.


was incorporated in 2015 and is headquartered in South San Francisco, California.

Market Data

Last Price 20.24
Change Percentage -2.46%
Open 20.7
Previous Close 20.75
Market Cap ( Millions) 1772
Volume 629809
Year High 47.72
Year Low 19.96
M A 50 23.69
M A 200 32.19

Financial Ratios

FCF Yield -14.19%
Dividend Yield 0.00%
ROE -26.74%
Debt / Equity 1.81%
Net Debt / EBIDTA 20.06%
Price To Book 1.56
Price Earnings Ratio -6.02
Price To FCF -7.05
Price To sales 253.11
EV / EBITDA -5.25

News

Business Breakdown

Expected Mid-Term Growth

Segment n°1 -> Oncology-focused Precision Medicine

Expected Growth : 15.4 %

What the company do ?

IDEAYA Biosciences' Oncology-focused Precision Medicine is a personalized approach to cancer treatment, leveraging DNA sequencing and AI to match patients with targeted therapies.

Why we expect these perspectives ?

Increasing adoption of precision medicine, advancements in DNA sequencing and AI, growing demand for targeted therapies, and rising cancer incidence rates drive growth in the oncology-focused precision medicine market.

Ideaya Biosciences, Inc. Products

Product Range What is it ?
Targeted Protein Degradation (TPD) Platform A novel approach to drug discovery that utilizes small molecules to selectively degrade disease-causing proteins, offering a potential solution for previously undruggable targets.
E3 Ligase Modulators Small molecule modulators that selectively engage E3 ubiquitin ligases to induce protein degradation, providing a new avenue for therapeutic intervention.
Cereblon Modulators Small molecule modulators that selectively engage the Cereblon E3 ubiquitin ligase to induce protein degradation, offering a potential solution for hematological malignancies and other diseases.
Degrader Conjugates A novel class of therapeutics that combine a targeting moiety with a degrader molecule, enabling the selective degradation of disease-causing proteins in specific cell types or tissues.
Protein Degradation Profiling Services Comprehensive profiling services that enable the identification of optimal degrader molecules and E3 ligase targets for specific disease indications.

IDEAYA Biosciences, Inc.'s Porter Forces

IDEAYA Biosciences, Inc. has a unique portfolio of precision medicine oncology products, which reduces the threat of substitutes.

IDEAYA Biosciences, Inc. has a diverse customer base, but some large pharmaceutical companies have significant bargaining power.

IDEAYA Biosciences, Inc. has a strong supply chain management system, which reduces the bargaining power of suppliers.

The biotechnology industry is highly competitive, and new entrants with innovative products can pose a significant threat to IDEAYA Biosciences, Inc.

The biotechnology industry is highly competitive, and IDEAYA Biosciences, Inc. faces intense rivalry from established players and new entrants.

Capital Structure

Value
Debt Weight 0.46%
Debt Cost 8.31%
Equity Weight 99.54%
Equity Cost 8.31%
WACC 8.31%
Leverage 0.46%

Historical Valuation

Price/Earnings Ratio

Margin Valuation

Peers Valuation

Competitors

Company Rational
TECH Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets worldwide. The company operates through two segments, …
INSM Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as …
ALNY Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, …
ADMA ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. …
BBIO BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging …

Peers Metrics

DCF BETA

Parameters

Short Term Growth
Short term Time
Long-Term Growth
WACC
Target Price
20.24$
Current Price
20.24$
Potential
-0.00%

Expected Cash-Flows

Scoring Insights

ValueQualityYieldMomentumVolatilityGrowth
Company A-Score: 6.20Peer Group Average: 4.80Leader: 4.80

Peers Group Analysis

🥇

Alnylam Pharmaceuticals Logo
Alnylam Pharmaceuticals
A-Score # N/A

Value:# N/A

Growth: # N/A

Quality: # N/A

Yield: # N/A

Momentum: # N/A

Volatility: # N/A

1-Year Total Return ->

🥈

ADMA Biologics Logo
ADMA Biologics
A-Score # N/A

Value:# N/A

Growth: # N/A

Quality: # N/A

Yield: # N/A

Momentum: # N/A

Volatility: # N/A

1-Year Total Return ->

🥉

Insmed Logo
Insmed
A-Score # N/A

Value:# N/A

Growth: # N/A

Quality: # N/A

Yield: # N/A

Momentum: # N/A

Volatility: # N/A

1-Year Total Return ->

4

Bio-Techne Logo
Bio-Techne
A-Score # N/A

Value:# N/A

Growth: # N/A

Quality: # N/A

Yield: # N/A

Momentum: # N/A

Volatility: # N/A

1-Year Total Return ->

5

BridgeBio Pharma Logo
BridgeBio Pharma
A-Score # N/A

Value:# N/A

Growth: # N/A

Quality: # N/A

Yield: # N/A

Momentum: # N/A

Volatility: # N/A

1-Year Total Return ->

6

IDEAYA Biosciences Logo
IDEAYA Biosciences
A-Score # N/A

Value:# N/A

Growth: # N/A

Quality: # N/A

Yield: # N/A

Momentum: # N/A

Volatility: # N/A

1-Year Total Return ->